Menlo Park, CA, United States of America

Sheau Yu Hsu

This inventor holds 14 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Leland Stanford Junior University. Active years: 2000-2023.

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 57.1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Mountain View, CA (US) (2000 - 2004)
Menlo Park, CA (US) (2007 - 2023)

Company Filing History:

14 out of 5,497

Leland Stanford Junior University

patents

Years Active: 2000-2023

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11666633 - Long-acting peptide analogs (2023-06-06),

2. 10058592 - Long-acting peptide analogs (2018-08-28),

3. 9815881 - Method of inducing labor or treating pre-eclampsia by administering relaxin analogs (2017-11-14),

4. 9694051 - Long-acting peptide analogs (2017-07-04),

5. 8481686 - Antibodies that bind stresscopin peptides (2013-07-09),

6. 8389475 - Relaxin analogs (2013-03-05),

7. 7829330 - Stresscopins and their uses (2010-11-09),

8. 7531313 - Screening for agents that modulate relaxin function (2009-05-12),

9. 7291341 - Stresscopins and their uses (2007-11-06),

10. 6780604 - Mammalian pro-apoptotic Bok genes and their uses (2004-08-24),

11. 6437097 - Mammalian pro-apoptotic Bok genes and their uses (2002-08-20),

12. 6376247 - Mammalian pro-apoptotic Bok genes and their uses (2002-04-23),

13. 6222017 - Mammalian pro-apoptotic Bok genes and their uses (2001-04-24),

14. 6043055 - Mammalian pro-apoptotic Bok genes and their uses (2000-03-28),

Title: Inventor Spotlight: Sheau Yu Hsu

Introduction

Sheau Yu Hsu is a prominent inventor based in Menlo Park, California, known for his significant contributions to the field of biotechnology. With an impressive portfolio of 14 patents, his work primarily focuses on the development of innovative peptide analogs that are critical in advancing therapeutic applications.

Latest Patents

Among his latest patents, Hsu has developed long-acting peptide analogs that serve as agonistic analogs for CLR/RAMP receptors. These innovations provide an extended half-life in vivo, which is crucial for enhancing the efficacy of therapeutic treatments. The importance of such advancements represents a significant leap in the biotechnology field, aiming to improve patient outcomes through sustained medication delivery.

Career Highlights

Sheau Yu Hsu is affiliated with Leland Stanford Junior University, where he conducts vital research and contributes to the academic community. His work not only emphasizes the importance of innovation in peptide therapeutics but also showcases his dedication to scientific advancement. Throughout his career, Hsu has made impactful strides that have influenced both research and clinical applications.

Collaborations

In his journey of innovation, Hsu has collaborated with esteemed colleagues, including Aaron J W Hsueh and Chia Lin Chang. These partnerships have fostered a collaborative environment that further enhances the research and development of new therapeutic solutions. The synergy within this team underscores the importance of teamwork in driving scientific breakthroughs.

Conclusion

Sheau Yu Hsu stands out as an inventive force in the biotechnology realm. His latest patents and ongoing research highlight the transformative potential of long-acting peptide analogs, positioning him as a key contributor to the future of medical treatments. As he continues to innovate and collaborate, the field of biotechnology eagerly anticipates the impact of his future endeavors.